| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H28ClN5O |
| Molecular Weight | 377.912 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1C(=O)N(CCCN2CCN(CC2)C3=CC(Cl)=CC=C3)N=C1CC
InChI
InChIKey=IZBNNCFOBMGTQX-UHFFFAOYSA-N
InChI=1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3
| Molecular Formula | C19H28ClN5O |
| Molecular Weight | 377.912 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Etoperidone is an atypical antidepressant introduced in Europe in 1977. The activity of etoperidone is made mainly by its major metabolite 1-(3'-chlorophenyl)piperazine (mCPP). mCPP binds with different affinity to most of the serotonergic receptors and adrenergic receptors. This metabolite is an agonist of 5-HT2c and an antagonist of 5-HT2a. Part of etoperidone structure contributes to the activity in the α-adrenergic receptors. Etoperidone has been studied for the treatment of depression, tremors in Parkinson, extrapyramidal symptoms and male impotence. It is not certain if it was ever approved and marketed but its current status is withdrawn.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 38.0 nM [Kd] | |||
| 570.0 nM [Kd] | |||
| 2.3 µM [Kd] | |||
| 85.0 nM [Kd] | |||
| 36.0 nM [Kd] |
PubMed
Patents
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 1 of 1 entries
